AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06202261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine tartrate injection
Description: Vinorelbine is an anti-tumor drug of vinca alkaloids.
Study NCT06514924 — intervention group
Intervention type: OTHER
Intervention: height and weight measurement
Description: Height and weight measurements and socioeconomic status survey
Study NCT05467709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 2 mg Day 1 and Day 16
Study NCT05467709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: 12 mg q12 hour for 14 consecutive days starting on Day 3
Study NCT05077683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 MG [Xarelto]
Description: Experimental group: usual DAPT strategy (aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily)) + rivaroxaban 2.5mg twice daily.
Study NCT05077683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAPT strategy
Description: usual DAPT strategy (aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily)) +
Study NCT05077683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAPT strategy
Description: usual DAPT strategy (aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily)) +
Study NCT06023303 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potenza
Description: The Radiofrequency microneedling device will be used for treating several skin problems. It is mostly used on the face and neck, specifically to treat jowls and firm the jawline, under aye area, and around the mouth.
Study NCT06023303 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Morpheus
Description: The Radiofrequency microneedling device will be used for treating several skin problems. It is mostly used on the face and neck, specifically to treat jowls and firm the jawline, under aye area, and around the mouth.
Study NCT05066347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiophone Plus
Description: Cardiophone Plus (Bittium Faros 360 Mobile event recorder, Bittium Biosignals Ltd., Finland., an external loop recorder with 3 leads for 2 channels. Cardiophone Plus evaluates all cardiac beats and rhythm abnormalities that are detected as per the algorithm programmed into the device. These abnormalities are then automatically and immediately transmitted to a central monitoring station without the need for any patient intervention (device-triggered transmission). This transmission occurs through the cell phone that comes with the device. The central monitoring station is in Windsor, Ontario (Canadian Cardiac Care) and is staffed round the clock by certified electrocardiographic technicians and a cardiologist on-call.
Study NCT06567236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D software
Description: Participants in the experimental arm will receive extra training on Planmeca Romexis Compare Software adapted to evaluate endodontic access preparation.
Study NCT06057233 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: mqMRI and GABA-MRS
Description: multiparametric quantitative MRI (mqMRI) and of GABA-edited magnetic resonance spectroscopy (GABA-MRS)
Study NCT06202261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate injection
Description: Eribulin induces G2/M phase cell cycle arrest, mitotic spindle division, and ultimately apoptosis after prolonged mitotic arrest through its tubulin-based anti-mitotic mechanism.
Study NCT06202261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride for injection
Description: Gemcitabine is a cell cycle specific anti-metabolic anticancer agent
Study NCT05395117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Participants will receive a single dose of midazolam in the morning of Day 1 and in the morning of Day 15 in both the arms.
Study NCT05395117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Participants will receive rosuvastatin as a single dose administered with digoxin at the same time in the morning of Day 2, Day 6, and in the morning of Day 16 in both the arms.
Study NCT05395117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Participants will receive digoxin as a single dose administered with rosuvastatin at the same time in the morning of Day 2, Day 6, and in the morning of Day 16 in both the arms.
Study NCT05017792 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Astrazenica vaccine
Description: COVID-19 vaccines should be administered by intramuscular (IM) injection, preferably into the deltoid muscle of the upper arm. Individuals who have minimal muscle mass in the deltoid area of the upper arm, or a particular reason to avoid immunization in the deltoid muscle, can be given their vaccine in the vastuslateralis muscle in the thigh if necessary.
Study NCT05370781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Led Diabetes Self-Management Support
Description: While the effectiveness of peer-led interventions delivering diabetes-related education and support for short-term clinical, psychosocial, and behavioral improvements is well-established, older Black men in particular are less likely to participate and are at a higher risk of drop-out from these studies. This intervention aims to determine if using older Black men as peer leaders to other older Black men will improve retention rates for this population.
Study NCT05370781 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Self-Management Education
Description: Participants will attend 10 hours of virtual group diabetes self-management education classes led by a certified diabetes care and education specialist through the online HIPPA compliant Zoom platform.
Study NCT05370781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Education
Description: Participants will attend 10 hours of virtual group diabetes self-management education classes led by a certified diabetes care and education specialist through the online HIPPA compliant Zoom platform.
Study NCT06081010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker Intervention
Description: Trained CHWs will hold group meetings or home visits using a locally adapted manual for HTN management. CHWs will visit homes in their areas and measure BP. High BP clients will be taken to the nearest health center. CHWs will enroll individuals with preHTN and HTN and conduct 4 follow-up group meetings or home visits with them every 3 months. Participants will be invited to attend CHW lead group-based counseling. For those with uncontrolled HTN who have difficulty adhering to prescribed HTN management and not willing or able to attend group meetings, CHWs will conduct follow-up home visits. First meeting (about 90 minutes), CHWs will explain purpose of the meeting and discuss HTN and its consequences. CHWs will apply techniques to initiate dialogue and reflection regarding lifestyle modifications and choose goals based on PEN protocol-2, BP monitoring, and antihypertensive medication use. In subsequent meetings (about 60 minutes), the CHWs will measure BP and address ongoing problems.
Study NCT06092827 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non weight-bearing physical activity program
Description: 12-week duration, 2 supervised trainings/week, 1 unsupervised home-based training/week Aerobic, resistance and flexibility exercises
Study NCT06584617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Berovenal®
Description: Easy to spread, water-washable, light brown, turbid hydrogel in tube containing 30 g of hydrogel and closed with a plastic screw cap.
Study NCT06584617 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NU-GEL Hydrogel with Alginate
Description: Transparent, easy to spread and water-washable hydrogel in ampoule (concertina pack) containing 25 g or 15 g of hydrogel and closed with a plastic cap.
Study NCT05105360 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure method of Petersen's space
Description: Surgeons closed Petersen's space between the mesentery of the jejunal Roux limb and the mesentery of the transverse colon at the posterior side of esophago-jejunostomy or gastro-jejunostomy from the mesentery root to the bowel side using a nonabsorbable barbed suture V-LocTM 3-0 (Medtronic VR, Minneapolis, MN, USA).
Study NCT05105360 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mesentery fixation method
Description: Surgeons fixed the jejunal mesentery (jejunojejunostomy\[J-J\] distal 30 cm) to the transverse mesocolon using non-absorbable barbed suture VLocTM 3-0 sutures. The suture area was exposed by grasping the jejunum side mesentery (jejunal side, at site 30cm distal J-J) and the transverse mesocolon (colonic side). The jejunal side mesentery was fixed to the colonic side mesocolon between the jejunum and the transverse colon using nonabsorbable barbed V-LocTM 3-0 sutures.The suture started between jejunal mesentery just below of SMA vascular arcade and transverse mesocolon, and it finished when it reaches the root of the mesentery. To anchor the mesentery, continuous suturing with V-Loc two-point backward sutures were performed at the final step.
Study NCT05881941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: using a soundproof nebulizer with a music and a funny mask added
Description: There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
Study NCT05881941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: using a silent nebulizer with no extra attachments
Description: There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
Study NCT05881941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: using a routinely employed nebulizer
Description: There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
Study NCT05357209 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Avidhrt Sense Heart Monitor
Description: Use of Avidhrt Sense Heart Monitor review ECG signals.
Study NCT06541977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral to reduce sedentary behvaior
Description: This intervention will also utilize a geographical time app to raise awareness about participants' sedentary lifestyles, helping them identify opportunities to incorporate more movement into their daily routines. Furthermore, the program will implement the Wheel of Change behavior technique, which serves as a structured approach to facilitate lasting changes in health behaviors, empowering participants to take control of their physical activity levels and overall well-being.
Study NCT06541977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: This intervention will be conducted with two weekly days of supervised and structured physical activity sessions, held at the university's facilities, providing participants with expert guidance and a supportive environment to enhance their physical fitness and overall health.
Study NCT06541977 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric Surgery
Description: In this intervention, bariatric surgery will be performed, accompanied by the usual hospital care, which includes comprehensive nutritional and physical activity advice. This standard care ensures that participants receive essential guidance and support for their dietary and exercise routines, complementing the surgical intervention.
Study NCT06541977 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery
Description: In this intervention, bariatric surgery will be performed, accompanied by the usual hospital care, which includes comprehensive nutritional and physical activity advice. This standard care ensures that participants receive essential guidance and support for their dietary and exercise routines, complementing the surgical intervention.
Study NCT06015217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetaphil Healing Ointment
Description: Subjects will use Cetaphil Healing Ointment on the diaper rash area with every diaper change
Study NCT03448601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally tailored brochure intervention group
Description: Culturally-tailored Alzheimer's Disease and precision medicine educational brochure.
Study NCT03448601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally tailored video intervention group
Description: Culturally-tailored Alzheimer's Disease and precision medicine educational video.
Study NCT05547932 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIB+SAP blocks
Description: RIB block will be performed after endotracheal intubation, then a SAP block will be performed. No other intervention will be performed to the patients.
Study NCT03890341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone/Ethinylestradiol
Description: A single oral dose of drospirenone/ethinylestradiol 3 mg/0.02 mg (OC) tablets will be administered on Days 1, 13 and 19.
Study NCT03890341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam 2 mg will be administered orally on Days 1, 13 and 19.
Study NCT03890341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64530440
Description: A single oral dose of JNJ-64530440 2,000 mg will be administered on Day 6 and once daily on Days 13 to 22.
Study NCT05955638 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiSight contact lenses
Description: Contact lens for myopia management.
Study NCT05955638 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proclear contact lenses
Description: Single vision contact lens as control
Study NCT05140278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argesun 60mg (1 step parenteral artesunate)
Description: Each vial of powder contains 60mg artesunate. Each ampoule of 6 ml solvent contains: sodium bicarbonate 8.4mg/ml; arginine 20mg/ml.
Study NCT05140278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesun 60mg (2-step parenteral artesunate)
Description: Each vial of powder contains 60 mg artesunate. Each ampoule of 1 ml solvent contains 50 mg sodium bicarbonate. Each ampoule of 5 ml diluent contains 45 mg sodium chloride.
Study NCT06057896 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: inositol, phytoestrogens, cocoa polyphenols
Description: myo-inositol, soy isoflavones and cocoa polyphenols
Study NCT05446740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK4382276A Dose level 1
Description: Dose level 1 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 1 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
Study NCT05446740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK4382276A Dose level 2
Description: Dose level 2 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 2 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
Study NCT05446740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK4382276A Dose level 3
Description: Dose level 3 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 3 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
Study NCT05446740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK4382276A Dose level 4
Description: Dose level 4 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 4 and OA GSK4382276A Dose level 4 groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
Study NCT05446740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK4382276A Dose level 6
Description: Dose level 6 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 6 group, at Day 1.
Study NCT05446740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK4382276A Dose level 7
Description: Dose level 7 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 7 group, at Day 1.
Study NCT05446740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK4382276A Dose level 8
Description: Dose level 8 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 8 group, at Day 1. Potential intermediate dose levels may be evaluated with the total number of dose levels not exceeding 10 in YA and 1 in OA.
Study NCT05446740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK4382276A Dose level 9
Description: Dose level 9 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 9 group, at Day 1. Potential intermediate dose levels may be evaluated with the total number of dose levels not exceeding 10 in YA and 1 in OA.
Study NCT05446740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK4382276A Dose level 10
Description: Dose level 10 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 10 group, at Day 1.
Study NCT05446740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK4382276A Dose level 11
Description: Dose level 11 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A level 11 group, at Day 1.
Study NCT04871724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Subjects will receive EDP-938 once daily on Days 1 and 14
Study NCT04871724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Subjects will receive fluconazole once daily on Days 5 to 18
Study NCT06422156 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation
Description: Patients will receive SBRT with doses ranging from 35-40 Gy in five fractions.
Study NCT05446740 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: FDQ21A-NH
Description: Single dose of FDQ21A-NH is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA Control 1 and OA Control groups, at Day 1.
Study NCT06422156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Patients will receive Nimotuzumab 400 mg weekly or Nimotuzumab 600mg on day 1 and 8 of a 21-day cycle until disease progression.
Study NCT05446740 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: FDQ22A-NH
Description: Single dose of FDQ21A-NH is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA Control 2, at Day 1.
Study NCT06422156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mono-chemotherapy
Description: Patients will receive mono-chemotherapy (Gemcitabine, S-1 or capecitabine) until disease progression.
Study NCT06574503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP681 40mg
Description: 2X20mg tablets taken orally
Study NCT06574503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GP681 Simulant
Description: Placebo tablets matching GP681 40mg
Study NCT04582864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flotetuzumab
Description: Will be provided by MacroGenics Inc.
Study NCT04582864 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor lymphocyte infusion
Description: DLI represents a non-specific form of adoptive cell therapy which involves infusion of a pool of allogeneic immune cells, including CD4+ T cells, CD8+ T cells, regulatory T cells (T Regs), natural killer (NK) cells and professional antigen presenting cells.
Study NCT06543004 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: AH plus sealer
Description: Root canal sealer will be placed inside the root canals during obturation procedure to seal dentine wall and reinforce the remaining tooth tissue.It will be selected randomly to the study samples.
Study NCT06543004 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Bioceramic sealer
Description: Root canal sealer will be placed inside the root canals during obturation procedure to seal dentine wall and reinforce the remaining tooth tissue.It will be selected randomly to the study samples.